Open an account

Dyne Therapeutics

DYN · NASDAQ

$16.27+$1.04 (+6.83%)TodayMarket closed ·
Prev close $15.23

About DYN

Dyne Therapeutics, Inc. is a clinical-stage company, which engages in developing innovative life-transforming therapies for genetically driven muscle diseases. The company is headquartered in Waltham, Massachusetts and currently employs 258 full-time employees. The company went IPO on 2020-09-17. The company is discovering and advancing therapeutics for people living with genetically driven neuromuscular diseases. Leveraging the modularity of its FORCE platform, it is developing targeted therapeutics that deliver to muscle and central nervous system (CNS). The company has a broad pipeline for neuromuscular diseases, including clinical programs for myotonic dystrophy type 1 and Duchenne muscular dystrophy and preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease. Its product candidate, zeleciment basivarsen (also known as DYNE-101), is being evaluated in ACHIEVE, an ongoing Phase I/II global clinical trial in patients with DM1. Its product candidate, zeleciment rostudirsen (also known as DYNE-251), is being evaluated in DELIVER, an ongoing Phase I/II global clinical trial in patients with DMD who have mutations amenable to skipping exon 51. Its other product candidates are DYNE-302 and DYNE-401.

Employees
258
Headquarters
Waltham, Massachusetts
Listed
Sep 17, 2020
Sector
Health Care
Industry
Biotechnology
Website
dyne-tx.com

DYN key statistics

Market cap
3.04B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
3.24M
Volume
3.40M
Open price
$15.27
High today
$16.56
Low today
$15.14
52 Week high
$27.31
52 Week low
$14.00

Dyne Therapeutics (DYN) at a glance

Dyne Therapeutics (DYN) last traded at $16.27, with a market cap of 3.04B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $15.14 and $16.56. The current price is 7.5% above the day's low and 1.8% below its high.

Volume so far is 3.40M shares, in line with the average of 3.24M shares a day.

Over the past year Dyne Therapeutics has ranged from $14.00 to $27.31, and now sits 17% of the way up that range.

Dyne Therapeutics met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$1.08 per share against an estimate of -$0.7582.

The average analyst price target is $37.35, 129.5% above the current price, from 13 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

85%of 13 analyst ratings say Buy
  • Buy84.6%
  • Hold7.7%
  • Sell7.7%
Price target · 15 analystsAvg $37.35
Low
$26.26
Now
$16.27
High
$52.50

DYN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 7.1% on average.

  1. Q3 FY24: reported -$0.96 per share against an estimate of -$0.7191
  2. Q4 FY24: reported -$0.88 per share against an estimate of -$0.9705
  3. Q1 FY25: reported -$1.05 per share against an estimate of -$0.888
  4. Q2 FY25: reported -$0.97 per share against an estimate of -$0.9642
  5. Q3 FY25: reported -$0.76 per share against an estimate of -$0.8457
  6. Q4 FY25: reported -$0.76 per share against an estimate of -$0.7777
  7. Q1 FY26: reported -$0.73 per share against an estimate of -$0.7808
  8. Q2 FY26: reported -$1.08 per share against an estimate of -$0.7582

DYN news

  • Vandana Singh

    Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling

  • Avi Kapoor

    Crude Oil Gains 1.5%; ABM Posts Upbeat Q3 Earnings

  • Avi Kapoor

    Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session

  • Press releaseGlobe Newswire

    Dyne Therapeutics to Participate in Upcoming Investor Conferences

  • Press releaseGlobe Newswire

    Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

  • Tanya Rawat

    Dyne Therapeutics Stock Tumbles After Hours: Here's Why

  • Press releaseGlobe Newswire

    Dyne Therapeutics to Participate in Upcoming Investor Conferences

  • Press releaseGlobe Newswire

    Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

Similar companies

Companies in the same industry as Dyne Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.